DelveInsight’s, “Frontotemporal Dementia Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Frontotemporal Dementia pipeline landscape. It covers the Frontotemporal Dementia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Frontotemporal Dementia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
“With the increasing numbers of promising treatments entering clinical trials, the Frontotemporal Dementia treatment market is expected to grow significantly in the coming years. There are currently 20+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment”
Key takeaways from the Frontotemporal Dementia Pipeline Insight Report
Recent Developmental Activities in the Frontotemporal Dementia Treatment Landscape
Discover the recent breakthroughs happening Frontotemporal Dementia pipeline landscape @ Frontotemporal Dementia Pipeline Outlook
Frontotemporal Dementia Overview
Frontotemporal dementia is an uncommon type of dementia that causes problems with behaviour and language. Dementia is the name for problems with mental abilities caused by gradual changes and damage in the brain. Frontotemporal dementia affects the front and sides of the brain (the frontal and temporal lobes).Dementia mostly affects people over 65, but frontotemporal dementia tends to start at a younger age. Most cases are diagnosed in people aged 45-65, although it can also affect younger or older people. Like other types of dementia, frontotemporal dementia tends to develop slowly and get gradually worse over several years. Signs of frontotemporal dementia can include: personality and behaviour changes – acting inappropriately or impulsively, appearing selfish or unsympathetic, neglecting personal hygiene, overeating, or loss of motivation, language problems – speaking slowly, struggling to make the right sounds when saying a word, getting words in the wrong order, or using words incorrectly, problems with mental abilities – getting distracted easily, struggling with planning and organisation.
Frontotemporal Dementia Emerging Drugs
PR 006 : Prevail Therapeutics
PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9.The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The European Commission has granted orphan designation for PR006 for the treatment of FTD.PR006 is currently being studied in our PROCLAIM trial, a Phase 1/2 clinical trial of PR006 for the treatment of patients with FTD-GRN.
Latozinemab : Alector
AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD-GRN). The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD-GRN.AL001 is being developed in collaboration with GSK.
PBFT 02 : Passage Bio
Passage Bio, gene therapy product candidate, PBFT02, an AAV1 viral vector to deliver a modified DNA encoding the granulin gene (GRN) to a patient’s cells. The vector will be delivered directly to the cerebrospinal fluid by a single injection to the cisterna magna (ICM injection). The goal of this vector and delivery approach is to provide higher-than-normal levels of the progranulin protein (PGRN) to the CNS to overcome the progranulin deficiency in GRN gene mutation carriers. Currently the product is in Phase I/II for the treatment of Frontotemporal Dementia.
WVE 004 : WaVe life Sciences
WVE-004 is an investigational variant-selective silencing candidate designed to selectively target the transcript variants containing a hexanucleotide repeat expansion (G4C2) in the C9orf72 gene, while sparing the healthy C9orf72 protein. G4C2 expansions are one of the most common genetic causes of the sporadic and inherited forms of ALS and FTD.
EXO 050 : Coya Therapeutics
EXO 050, is the lead drug candidate of Coya Therapeutics for the treatment of FTD.Currently, the drug is in Pre-Clinical stage of development for the treatment of FTD.
To find out more facts about the Frontotemporal Dementia Emerging Drugs, visit for more information @ Frontotemporal Dementia Ongoing Clinical Trials
Frontotemporal Dementia Therapeutic Assessment
There are approx. 20+ key companies which are developing the therapies for Frontotemporal Dementia. The Frontotemporal Dementia Companies which have their Frontotemporal Dementia drug candidates in the most advanced stage, i.e. phase III include, Alector.
Frontotemporal Dementia Therapeutics Segmentation
The Frontotemporal Dementia Pipeline report proffers an integral view of the Frontotemporal Dementia emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Learn more about the novel Frontotemporal Dementia emerging therapies @ Frontotemporal Dementia Treatment Landscape
Scope of the Frontotemporal Dementia Pipeline Report
Table of Content
For further information on the Frontotemporal Dementia current pipeline therapeutics, reach out to Frontotemporal Dementia Key Companies and Therapies
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/brucellosis-market